Aditya Birla Finance lists commercial papers on NSE

Aditya Birla Finance lists commercial papers on NSE

ABFL listed its CPs on NSE with a value date of November 28, 2019 and maturity date on February 7, 2020.

FPJ BureauUpdated: Friday, November 29, 2019, 08:52 AM IST
article-image

New Delhi: National Stock Exchange of India (NSE) said non-banking financial company Aditya Birla Finance (ABFL) became the first company to list commercial papers (CP) on its platform.

ABFL listed its CPs on NSE with a value date of November 28, 2019 and maturity date on February 7, 2020.

"Trust in the system can only be restored with complete transparency. Through this pioneering move, we aim to set standards for commercial paper issuance which will bring in liquidity, transparency and thereby create trust in the minds of investors," Aditya Birla Finance managing director and CEO, Rakesh Singh, said in a statement.

In October, the capital markets regulator Securities and Exchange Board of India (Sebi) asked exchanges to put in place a necessary framework for systems and procedures for listing of commercial papers.

Companies, NBFCs with a net worth of at least Rs 100 crore and any other security specifically llowed by Reserve Bank of India (RBI) are eligible to list CPs.

RECENT STORIES

FLY91 Launches Daily Kochi–Agatti Flights, Announces Expansion To 7 New Regional Stations
FLY91 Launches Daily Kochi–Agatti Flights, Announces Expansion To 7 New Regional Stations
Gold Breaches ₹1.5 Lakh Per 10 Grams Mark; Silver Surges To Record ₹3.23 Lakh Per Kg
Gold Breaches ₹1.5 Lakh Per 10 Grams Mark; Silver Surges To Record ₹3.23 Lakh Per Kg
Investors’ Wealth Erodes By ₹9.86 Lakh Crore As Stock Markets Tumble
Investors’ Wealth Erodes By ₹9.86 Lakh Crore As Stock Markets Tumble
Canada–China Trade Deal Ill-Timed And One-Sided Amid Unresolved Disputes: Report
Canada–China Trade Deal Ill-Timed And One-Sided Amid Unresolved Disputes: Report
Concept Medical Launches Global Trial On Next-Gen Drug-Eluting Stent
Concept Medical Launches Global Trial On Next-Gen Drug-Eluting Stent